BCL2 and acute myeloid leukemia: Venetoclax (Ven) is a B-cell leukemia/lymphoma-2 (BCl-2) inhibitor that is currently widely used in clinical practice for the following AML patient populations: patients ineligible for intensive chemotherapy, patients with refractory/relapsed disease, and even newly diagnosed AML patients eligible for intensive chemotherapy.